Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Biotechnology_CAR-T (Chimeric Antigen Receptors-T Cell), T Cell Engager (TCE) & T-Cell Research
Servier*

Organization & Developments: Servier

Parents

2011: MacroGenics signs big pharma deal with Servier (2011)
2020: Agios pivots away from oncology, auctioning off cancer pipeline for $2B and shifting the spotlight in restructuring
2020: Agios sells cancer business to French drug maker Servier for up to $2 billion
2021: Valence Discovery Announces Multi-Target AI-Enabled Drug Design Collaboration with Servier
Corporate growth is driven by Servier’s constant commitment in five areas of excellence: cardiovascular, immune-inflammatory, and neurodegenerative diseases, cancer and diabetes, as well as by its activities in high-quality generic drugs. Servier also offers eHealth solutions beyond drug development.
Entirely independent, the Group invests on average 25% of its total revenue (excluding generics) every year in research and development and uses all its profits for its development.
Servier is an international pharmaceutical company governed by a non-profit foundation, with its headquarters in France (Suresnes).
Servier Laboratories (Ireland) Limited
With a strong international presence in 150 countries and a total revenue of 4.6 billion euros in 2019, Servier